WEIGUANG BIOLOGICAL(002880) Guohai Securities·2024-10-29 06:10Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2][4]. Core Insights - The company has shown significant revenue and profit growth in Q3 2024, with a year-over-year revenue increase of 19.02% and a net profit increase of 45.05% [3][4]. - The company has received multiple product approvals, enhancing its product portfolio and demonstrating confidence through an employee stock ownership plan [4]. - The projected revenues for 2024, 2025, and 2026 are estimated at 1.217 billion yuan, 1.406 billion yuan, and 1.608 billion yuan respectively, with corresponding net profits of 247 million yuan, 290 million yuan, and 337 million yuan [4][6]. Financial Performance Summary - For the first three quarters of 2024, the company reported revenues of 854 million yuan, a 16.14% increase year-over-year, and a net profit of 183 million yuan, up 20.80% year-over-year [3][4]. - In Q3 2024, the gross margin was reported at 41.66%, a decrease of 2.47 percentage points year-over-year, while the net profit margin improved by 3.85 percentage points to 21.98% [4]. - The company’s total market capitalization is approximately 6.577 billion yuan, with a circulating market value of about 6.555 billion yuan [4]. Valuation Metrics - The report provides a forecast for the company's earnings per share (EPS) to be 1.09 yuan in 2024, 1.28 yuan in 2025, and 1.49 yuan in 2026, with a projected price-to-earnings (P/E) ratio of 26.58X for 2024 [6][8]. - The return on equity (ROE) is expected to improve from 11% in 2023 to 13% by 2026 [8].